Literature DB >> 3325215

The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis.

P J Perry1, B M Pfohl, S G Holstad.   

Abstract

The relationship between the antidepressant effect of the tricyclic antidepressants and their plasma concentrations was reviewed. Logistic regression was utilised as an analytical tool to facilitate the evaluation. The currently available literature allowed the construction of 4 tricyclic data sets of sufficient size to warrant statistical analysis. Inspection of the distribution of the data and the logistic regression analyses resulted in several conclusions regarding the existence of 'therapeutic windows' for these drugs. Firstly, no relationship between amitriptyline plasma concentrations and therapeutic response was apparent. Secondly, curvilinear relationships were apparent for 2 of the other tricyclic antidepressants studied. The currently recommended therapeutic range of 60 to 150 micrograms/L for nortriptyline was found to be the range most likely to produce a positive antidepressant effect. Desipramine concentrations between 108 and 158 micrograms/L were most commonly associated with beneficial therapeutic responses. Finally, a linear relationship was noted for imipramine in which an imipramine therapeutic plasma concentration threshold of 244 micrograms/L and above was most commonly associated with a beneficial response to the drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3325215     DOI: 10.2165/00003088-198713060-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  27 in total

1.  Plasma-nortriptyline levels in endogenous depression.

Authors:  P Kragh-Sørensen; M Asberg; C Eggert-Hansen
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

Review 2.  Tricyclic antidepressants--blood level measurements and clinical outcome: an APA Task Force report. Task Force on the Use of Laboratory Tests in Psychiatry.

Authors: 
Journal:  Am J Psychiatry       Date:  1985-02       Impact factor: 18.112

3.  Relationship of free nortriptyline levels to therapeutic response.

Authors:  P J Perry; J L Browne; B Alexander; B M Pfohl; F J Dunner; A D Sherman; M T Tsuang
Journal:  Acta Psychiatr Scand       Date:  1985-08       Impact factor: 6.392

4.  A double-blind comparison of dothiepin and amitriptyline in patients with primary affective disorder: serum levels and clinical response.

Authors:  J Mendlewicz; P Linkowski; J A Rees
Journal:  Br J Psychiatry       Date:  1980-02       Impact factor: 9.319

5.  Clinical response, plasma levels and pharmacokinetics of desipramine in depressed in-patients.

Authors:  P D Hrdina; Y D Lapierre
Journal:  Prog Neuropsychopharmacol       Date:  1980

6.  Plasma levels and antidepressive effect of imipramine.

Authors:  L F Gram; N Reisby; I Ibsen; A Nagy; S J Dencker; P Bech; G O Petersen; J Christiansen
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

7.  Plasma levels, psychophysiological variables, and clinical response to amitriptyline.

Authors:  U Breyer-Pfaff; H J Gaertner; H Giedke
Journal:  Psychiatry Res       Date:  1982-04       Impact factor: 3.222

8.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

9.  Self-inhibiting action of nortriptylin's antidepressive effect at high plasma levels: a randomized double-blind study controlled by plasma concentrations in patients with endogenous depression.

Authors:  P Kragh-Sorensen; C E Hansen; P C Baastrup; E F Hvidberg
Journal:  Psychopharmacologia       Date:  1976-02-02

10.  Endogenous depression and imipramine levels in the blood.

Authors:  D Costa; V Predescu; I Vişan-Ionescu; T Ciurezu
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  17 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring of psychotropic medications.

Authors:  P B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

3.  Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression.

Authors:  Sven Ulrich; Jürgen Läuter
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Aspects of amitriptyline and nortriptyline plasma levels monitoring in depression.

Authors:  G L Corona; M L Cucchi; P Frattini; G Santagostino; S Schinelli; F Zerbi; F Savoldi
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

8.  Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant; G Garrone
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

9.  P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.

Authors:  Fionn E O'Brien; Richard M O'Connor; Gerard Clarke; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Neuropsychopharmacology       Date:  2013-05-14       Impact factor: 7.853

Review 10.  Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness.

Authors:  R Eilers
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.